Ropivacaine Market Size, Share, and COVID-19 Impact Analysis, By Administration (Epidural, Infiltration, and Others), By Indication (Surgical Anesthesia and Acute Pain Management), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Ropivacaine is a local and regional anesthetic used during surgery and for short-term pain management such as postoperative and labor pain management. There is an increasing rate of major surgeries such as cardiovascular surgeries, general surgeries, and others that require anesthesia. This is increasing the demand for anesthetic injections such as ropivacaine among patients, further contributing to the rising adoption of ropivacaine injections in the market.

• For instance, according to a 2022 news published by National Heart, Lung, and Blood Institute, approximately 2.0 million people underwent open-heart surgery, worldwide. Ropivacaine is generally used as an anesthesia for short-term pain management during these surgeries, thus increasing its adoption and contributing to the market’s growth.

Moreover, the geriatric population is at higher risk of developing chronic disorders such as heart disorders, neurovascular disorders, and others, which is expected to increase the rate of surgeries performed among this population. An increasing number of surgeries require anesthetics for post-operative pain management which is likely to increase the adoption of anesthetics in the upcoming years.

Additionally, certain advantages associated with ropivacaine such as improved penetration rate, lower concentration required, and others as compared to other commercially available anesthetics is contributing to the rising adoption of ropivacaine among patients. Also, ropivacaine is associated with minimal chances of motor block, making it suitable for administering in patients. Thus, the increasing number of surgeries coupled with rising drug adoption increases the demand for ropivacaine, further enabling the key players to focus on launching ropivacaine and its generics in the market.

• According to a 2022 article published by the European Journal of Molecular & Clinical Medicine, it was reported that ropivacaine has an added advantage over other anesthetics such as bupivacaine, which has prolonged analgesia duration leading to lesser requirement of ropivacaine among patients.

Impact of COVID-19 on the Ropivacaine Market 

The COVID-19 pandemic has negatively impacted the ropivacaine market. The sales of ropivacaine decreased rapidly as a massive decline was observed in surgical procedures during the pandemic. Decreased surgical procedures affected the adoption of ropivacaine among the patient population, leading to decreased demand for ropivacaine in the market. According to a 2022 article published by National Center for Biotechnology Information (NCBI), it was reported that significantly fewer operations were performed due to fewer inpatient and outpatient admissions during the pandemic.

• For instance, according to a 2021 article published by JAMA Network, it was reported that there was a 48.0% decrease in total surgical procedures during the COVID-19 period.

Moreover, the pandemic resulted in a heavy disruption in the supply chain which made it difficult for industries and organizations to distribute ropivacaine during the pandemic and decreased the demand for ropivacaine among the patient population. 

Key Insights: 

• Number of Key Surgeries Performed In Key Countries, 2022.
• Prevalence of Chronic Pain, By Key Countries, 2022.
• Pricing Analysis, By Key Brands.
• Key Industry developments- Partnerships, Mergers, and Acquisitions.
• Impact of COVID-19 on the Ropivacaine Market.

Analysis by Product:

Based on the product, the market is bifurcated into epidural administration, infiltration, and others. Amongst these, epidural administration is dominant in the market owing to its distinct advantages such as its effectiveness, adequate pain control without affecting the sensation of pressure, and others. Also, epidural administration is preferred in general surgery due to its use as a sole anesthetic during surgery and as a continuous infusion for postoperative pain control.

• For instance, according to a 2022 article published by the International Journal of Gynecology & Obstetrics, it is reported that lumbar epidural is the most effective form of pain relief in labor, with around 30% of laboring women in the U.K. and 60% in the U.S. receiving epidural analgesia.

On the other hand, infiltration generally provides anesthesia for minor surgical procedures and also improves postoperative analgesia. The increasing patient population undergoing minor surgical procedures is leading to the rising demand for this method of administration among patients and thus, contributing to the growth of the segment in the market.

Regional Analysis:

To gain extensive insights into the market, Download for Customization

North America market holds the largest share due to the increasing number of surgeries such as cesarean surgery that require anesthetics in order to manage the labor pain among pregnant women is expected to increase its demand. An increasing number of surgeries along with improved reimbursement policies in the region further supports the adoption of ropivacaine among the patient population, further increasing the demand for ropivacaine in the market.  This is leading the key players to focus on receiving regulatory approvals for introducing anesthetics such as ropivacaine into the market. Furthermore, increasing regulatory approvals for these anesthetics contributed to the increased availability of ropivacaine, thereby supporting the growth of the market.

• For instance, according to a 2021 article published by the march of Dimes, it was reported that 32.1% of live births were from cesarean deliveries in the U.S.

On the other hand, Asia Pacific is anticipated to register a considerable growth rate. This is attributed to the increasing geriatric population, resulting in more operative procedures among patients. This, along with growing awareness about the advantages of ropivacaine over other anesthetics and rising healthcare expenditure is leading to the region's growth in the market.

Key Players:

The report will include the profiles of key players such as Pfizer Inc., AstraZeneca, Aspen Pharmacare, Akorn Operating Company LLC, Nephron Pharmaceuticals Corporation, and others

Segmentation:

Key Industry Developments:

• December 2020: Hikma launched ropivacaine HCl anesthetic injection for surgery and acute pain management in the U.S. 
• April 2020: Caplin Steriles received U.S. FDA approval for Ropivacaine hydrochloride injection with an aim to widen its product portfolio.